PL2893019T3 - siRNA i jego zastosowanie w sposobach i kompozycjach do leczenia i/lub zapobiegania chorobom oczu - Google Patents

siRNA i jego zastosowanie w sposobach i kompozycjach do leczenia i/lub zapobiegania chorobom oczu

Info

Publication number
PL2893019T3
PL2893019T3 PL13759707T PL13759707T PL2893019T3 PL 2893019 T3 PL2893019 T3 PL 2893019T3 PL 13759707 T PL13759707 T PL 13759707T PL 13759707 T PL13759707 T PL 13759707T PL 2893019 T3 PL2893019 T3 PL 2893019T3
Authority
PL
Poland
Prior art keywords
sirna
prevention
compositions
treatment
methods
Prior art date
Application number
PL13759707T
Other languages
English (en)
Polish (pl)
Inventor
Ana Isabel Jimenez Anton
Victoria GONZALEZ FAJARDO
Veronica RUZ PALOMAR
Original Assignee
Sylentis S.A.U.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sylentis S.A.U. filed Critical Sylentis S.A.U.
Publication of PL2893019T3 publication Critical patent/PL2893019T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL13759707T 2012-09-05 2013-09-04 siRNA i jego zastosowanie w sposobach i kompozycjach do leczenia i/lub zapobiegania chorobom oczu PL2893019T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1215857.2A GB201215857D0 (en) 2012-09-05 2012-09-05 siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
PCT/EP2013/068245 WO2014037377A1 (en) 2012-09-05 2013-09-04 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
EP13759707.6A EP2893019B1 (en) 2012-09-05 2013-09-04 Sirna and its use in methods and compositions for the treatment and/or prevention of eye conditions

Publications (1)

Publication Number Publication Date
PL2893019T3 true PL2893019T3 (pl) 2018-12-31

Family

ID=47136985

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13759707T PL2893019T3 (pl) 2012-09-05 2013-09-04 siRNA i jego zastosowanie w sposobach i kompozycjach do leczenia i/lub zapobiegania chorobom oczu

Country Status (29)

Country Link
US (1) US9808479B2 (h)
EP (1) EP2893019B1 (h)
JP (2) JP2015529210A (h)
KR (1) KR102136539B1 (h)
CN (2) CN104640988A (h)
AU (1) AU2013311781B2 (h)
BR (1) BR112015004469B8 (h)
CA (1) CA2883040C (h)
CL (1) CL2015000537A1 (h)
CY (1) CY1121000T1 (h)
DK (1) DK2893019T3 (h)
EC (1) ECSP15009391A (h)
ES (1) ES2685346T3 (h)
GB (1) GB201215857D0 (h)
HR (1) HRP20181079T1 (h)
HU (1) HUE040096T2 (h)
IL (1) IL237389B (h)
IN (1) IN2015DN02501A (h)
LT (1) LT2893019T (h)
MX (1) MX362854B (h)
PE (1) PE20150619A1 (h)
PL (1) PL2893019T3 (h)
PT (1) PT2893019T (h)
RS (1) RS57620B1 (h)
RU (1) RU2663100C2 (h)
SG (1) SG11201501386TA (h)
SI (1) SI2893019T1 (h)
WO (1) WO2014037377A1 (h)
ZA (1) ZA201501494B (h)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX342731B (es) 2011-06-30 2016-10-11 Arrowhead Res Corp Composiciones y metodos para inhibir la expresion genica del virus de hepatitis b.
KR20180038465A (ko) 2015-08-07 2018-04-16 애로우헤드 파마슈티컬스 인코포레이티드 Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
PH12021551968A1 (en) 2019-02-15 2022-05-23 Novartis Ag Methods for treating ocular surface pain
DK4043014T3 (da) * 2019-10-04 2025-06-23 Senju Pharma Co Farmaceutisk sammensætning indeholdende heterocyklidenacetamid-derivat til brug til behandling af tørre øjne

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343794A (en) 1980-05-06 1982-08-10 Mt. Sinai Method of reducing intraocular pressure with salts of vanadic acid
US4652586A (en) 1980-11-07 1987-03-24 The General Hospital Corporation Selective beta-2 adrenergic antagonists for the treatment of glaucoma
US4617299A (en) 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US5242943A (en) 1984-03-28 1993-09-07 William J. Louis 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them
US4812448A (en) 1984-10-22 1989-03-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4757089A (en) 1985-06-14 1988-07-12 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US5075323A (en) 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
US5260059A (en) 1989-04-14 1993-11-09 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor
US6372249B1 (en) 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5464866A (en) 1992-08-17 1995-11-07 Alcon Laboratories, Inc. Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
US5545626A (en) 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US20020055536A1 (en) 1996-09-26 2002-05-09 Dewitte Robert S. System and method for structure-based drug design that includes accurate prediction of binding free energy
US6489307B1 (en) 1998-09-14 2002-12-03 University Of Florida Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
US6365576B1 (en) 1999-06-24 2002-04-02 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for inhibiting herpes infection
PL218876B1 (pl) 2000-12-01 2015-02-27 Europaisches Lab Für Molekularbiologie Embl Wyizolowana cząsteczka dwuniciowego RNA, sposób wytwarzania cząsteczki dwuniciowego RNA, zastosowanie cząsteczki dwuniciowego RNA do wytwarzania leku do modulowania działania genu związanego z patogenem, genu związanego z nowotworem, oraz genu związanego z chorobą autoimmunologiczną, sposób in vitro kierowania miejscowo specyficznymi interferencjami RNA w komórce, zastosowanie sposobu in vitro do ustalania działania genu w komórce oraz do modulowania działania genu w komórce, środek farmaceutyczny, komórka eukariotyczna transfekowana cząsteczką RNA lub cząsteczką DNA kodującą tę cząsteczkę RNA, oraz zastosowanie komórki eukariotycznej w procedurach analitycznych oraz w procedurach preparatywnych
US20020165158A1 (en) 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20070049543A1 (en) 2001-05-18 2007-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20030148987A1 (en) 2001-12-21 2003-08-07 Morris David J. Selective 11beta-HSD inhibitors and methods of use thereof
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
GB2406568B (en) 2002-02-20 2005-09-28 Sirna Therapeutics Inc RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
WO2003087368A2 (en) 2002-04-18 2003-10-23 Lynkeus Bio Tech Gmbh Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
US20040115641A1 (en) 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of ROCK 1 expression
US20040146858A1 (en) 2002-07-24 2004-07-29 Immusol, Inc. Novel siRNA gene libraries and methods for their production and use
JP2005533504A (ja) 2002-07-24 2005-11-10 イミューソル インコーポレイテッド ポリメラーゼプライマーヘアピンリンカーを用いたｓｉＲＮＡ発現カセット及び発現ライブラリーの製造用単一プロモーター系
ES2280826T5 (es) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
US20040029275A1 (en) 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
WO2004029212A2 (en) 2002-09-25 2004-04-08 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
US7521431B2 (en) 2002-11-01 2009-04-21 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of HIF-1 alpha
DE10322662A1 (de) 2002-11-06 2004-10-07 Grünenthal GmbH Wirksame und stabile DNA-Enzyme
ES2440284T3 (es) 2002-11-14 2014-01-28 Thermo Fisher Scientific Biosciences Inc. ARNip dirigido a tp53
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20060257851A1 (en) 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US20040167090A1 (en) 2003-02-21 2004-08-26 Monahan Sean D. Covalent modification of RNA for in vitro and in vivo delivery
GB0307206D0 (en) 2003-03-28 2003-04-30 Axordia Ltd Hyperproliferation
US20040198640A1 (en) 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US7462602B2 (en) 2003-05-01 2008-12-09 University Of Florida Research Foundation, Inc. Anti-scarring ribozymes and methods
US20040224405A1 (en) 2003-05-06 2004-11-11 Dharmacon Inc. siRNA induced systemic gene silencing in mammalian systems
WO2005044976A2 (en) 2003-06-20 2005-05-19 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
CA2541299A1 (en) 2003-10-07 2005-04-14 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
KR20050039573A (ko) 2003-10-23 2005-04-29 주식회사 태평양 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물
WO2005045037A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050208658A1 (en) 2003-11-21 2005-09-22 The University Of Maryland RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression
KR101350837B1 (ko) * 2003-12-03 2014-01-14 코다 테라퓨틱스, 인크. 코넥신에 표적화된 안티센스 화합물 및 그의 사용 방법
US7544803B2 (en) 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US20090247604A1 (en) 2004-02-05 2009-10-01 Intradigm Corporation RNAi Therapeutics for Treatment of Eye Neovascularization Diseases
GB0403600D0 (en) 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease
AU2005222902B2 (en) 2004-03-12 2010-06-10 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
WO2005117938A2 (en) 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methods of treating ocular conditions
JP2008504280A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション ２−メチルプロパンアミドおよびその医薬としての使用
CA2576233C (en) 2004-08-10 2016-03-15 Alnylam Pharmaceuticals, Inc. Conjugate comprising an antagomir and a ligand
JP5766900B2 (ja) 2004-08-23 2015-08-19 シレンティス・エセ・ア・ウ 眼内圧の上昇によって特徴付けられる眼の疾患のｓｉＲＮＡによる治療
TW200639253A (en) 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets
WO2006099353A1 (en) 2005-03-11 2006-09-21 Alcon, Inc. Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
GB0521351D0 (en) 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
EP2059597A2 (en) * 2006-08-24 2009-05-20 Alcon Research, Ltd. Rnai-mediated inhibition of gremlin for treatment of iop-related conditions
WO2009023025A1 (en) 2007-08-13 2009-02-19 Board Of Trustees Of Southern Illinois University Methods for treatment and prevention of ototoxicity by sirna
TW200927192A (en) 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
CN201337650Y (zh) * 2009-01-06 2009-11-04 河北科技大学 一次性药用单剂量液体容器
EP2390327A1 (en) * 2010-05-27 2011-11-30 Sylentis S.A. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions

Also Published As

Publication number Publication date
MX2015002802A (es) 2015-05-15
LT2893019T (lt) 2018-08-10
BR112015004469B8 (pt) 2022-12-06
MX362854B (es) 2019-02-20
BR112015004469B1 (pt) 2022-11-16
HK1212377A1 (en) 2016-06-10
ES2685346T3 (es) 2018-10-08
IL237389B (en) 2019-01-31
CN104640988A (zh) 2015-05-20
AU2013311781B2 (en) 2018-10-18
SI2893019T1 (sl) 2018-09-28
RU2663100C2 (ru) 2018-08-01
JP2018138596A (ja) 2018-09-06
EP2893019B1 (en) 2018-05-30
EP2893019A1 (en) 2015-07-15
ECSP15009391A (es) 2015-12-31
JP6742362B2 (ja) 2020-08-19
BR112015004469A2 (pt) 2017-08-08
HRP20181079T1 (hr) 2018-09-07
CA2883040C (en) 2023-01-17
KR20150047513A (ko) 2015-05-04
WO2014037377A1 (en) 2014-03-13
JP2015529210A (ja) 2015-10-05
CY1121000T1 (el) 2019-12-11
PE20150619A1 (es) 2015-05-11
IN2015DN02501A (h) 2015-09-11
KR102136539B1 (ko) 2020-07-23
CN108354944A (zh) 2018-08-03
RU2015112121A (ru) 2016-10-27
IL237389A0 (en) 2015-04-30
HUE040096T2 (hu) 2019-02-28
AU2013311781A1 (en) 2015-03-12
CA2883040A1 (en) 2014-03-13
US20150224131A1 (en) 2015-08-13
RS57620B1 (sr) 2018-11-30
US9808479B2 (en) 2017-11-07
PT2893019T (pt) 2018-10-19
SG11201501386TA (en) 2015-03-30
CL2015000537A1 (es) 2015-07-10
GB201215857D0 (en) 2012-10-24
ZA201501494B (en) 2016-01-27
DK2893019T3 (en) 2018-09-03

Similar Documents

Publication Publication Date Title
EP2817018A4 (en) METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS
ZA201402615B (en) Prevention and treatment of ocular conditions
IL237528B (en) Methods for preventing and treating preeclampsia
EP2831001A4 (en) COMPOSITION FOR THE TREATMENT OF WATER AND METHOD FOR USE
GB201217296D0 (en) Method of treatment and/or prevention
ZA201408056B (en) Compositions and methods for the treatment of mucositis
ZA201408055B (en) Compositions and methods for the treatment of local pain
SI2576782T1 (sl) siRNA in njena uporaba v postopkih in sestavkih za zdravljenje in/ali preprečevanje očesnih stanj
PL2854910T3 (pl) Poziomy ceramidu w leczeniu i zapobieganiu infekcjom
EP2869819A4 (en) COMPOSITIONS, METHODS AND / OR DEVICES FOR THE PREVENTION AND / OR TREATMENT OF OCULAR DROUGHT DISORDERS
HUE044216T2 (hu) Kitin vagy annak származékai parazitózisok megelõzésére és/vagy kezelésére
ZA201501494B (en) Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
ZA201502181B (en) Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
IL222482A0 (en) Methods and compositions for the treatment of fluid accumulation in and/or under the retina
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
ZA201408065B (en) Compositions and methods for the treatment of diabetes
PT2862576T (pt) Microrganismos e composições que os compreendem para utilização no tratamento ou prevenção de mastite
SG11201500838UA (en) Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof
IL243237A0 (en) Methods and preparations for the treatment of fluid accumulation in and/or under the retina
AU2012902937A0 (en) Composition for prevention and treatment of eye disorder
ZA201501068B (en) Methods for prevention and treatment of preeclampsia